On March 14, 2023, the FDA amended the Emergency Use Authorization (EUA) for the bivalent Pfizer-BioNTech COVID-19 vaccine booster. In a previous entry to the EUA, the bivalent booster was to be administered two months after the completion of the primary vaccination with three doses of the monovalent (single strain) Pfizer-BioNTech COVID-19 vaccine. With this update, the Pfizer-BioNTech COVID-19 Vaccine is no longer authorized for use as the third dose of the primary series in individuals 6 months through 4 years of age. Effective March 14, 2023, use new CPT code for Pfizer-BioNTech COVID-19 Vaccine, Bivalent - Administration – Booster Dose:
CPT Code: 0174A
Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose
Short descriptor: ADM SARSCV2 BVL 3MCG/0.2ML B